Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:The global impact of the COVID-19 pandemic on the management and course of chronic urticaria
Avtorji:ID Kocatürk, Emek (Avtor)
ID Salman, Andaç (Avtor)
ID Cherrez-Ojeda, Ivan (Avtor)
ID Criado, Paulo Ricardo (Avtor)
ID Peter, Jonny (Avtor)
ID Comert-Ozer, Elif (Avtor)
ID Abuzakouk, Mohamed (Avtor)
ID Câmara Agondi, Rosana (Avtor)
ID Al-Ahmad, Mona (Avtor)
ID Altrichter, Sabine (Avtor)
ID Bizjak, Mojca, Klinika Golnik (Avtor)
ID Košnik, Mitja, Klinika Golnik, Medicinska fakulteta UL (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.14687
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Introduction: The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: To understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: Our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: The COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19. Conclusions: The COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation.
Ključne besede:chronic urticaria, pandemics, omalizumab, cyclosporine, COVID-19, SARS-CoV-2, UCARE, treatment
Status publikacije:V tisku
Verzija publikacije:Recenzirani rokopis
Kraj izida:Velika Britanija
Založnik:John Wiley & Sons
Leto izida:2020
Št. strani:str. [1-39]
Številčenje:Vol. 75, iss.
PID:20.500.12556/DiRROS-12897 Novo okno
UDK:616-097
ISSN pri članku:1398-9995
DOI:10.1111/ALL.14687 Novo okno
COBISS.SI-ID:42049795 Novo okno
Avtorske pravice:John Wiley & Sons
Opomba:Nasl. z nasl. zaslona; Soavtorja iz Slovenije: Mojca Bizjak, Mitja Košnik; Opis vira z dne 10. 12. 2020;
Datum objave v DiRROS:14.12.2020
Število ogledov:2194
Število prenosov:535
Metapodatki:XML DC-XML DC-RDF
:
KOCATÜRK, Emek, SALMAN, Andaç, CHERREZ-OJEDA, Ivan, CRIADO, Paulo Ricardo, PETER, Jonny, COMERT-OZER, Elif, ABUZAKOUK, Mohamed, CÂMARA AGONDI, Rosana, AL-AHMAD, Mona, ALTRICHTER, Sabine, BIZJAK, Mojca in KOŠNIK, Mitja, 2020, The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy [na spletu]. 2020. Vol. 75, p. 1–39. [Dostopano 26 marec 2025]. DOI 10.1111/ALL.14687. Pridobljeno s: https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.14687
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Allergy
Založnik:Blackwell
ISSN:1398-9995
COBISS.SI-ID:515009305 Novo okno

Sekundarni jezik

Jezik:Ni določen
Ključne besede:kronična urtikarija, pandemije, omalizumab, ciklosporin, covid-19, SARS-CoV-2, UCARE, zdravljenje


Nazaj